Drug Profile
Aducanumab - Neurimmune Therapeutics
Alternative Names: Aducanumab-avwa; ADUHELM; Anti-beta amyloid monoclonal antibody - Biogen/Neurimmune Therapeutics; BART; BIIB 037; NI-10Latest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Neurimmune Therapeutics; University of Zurich
- Developer Neurimmune Therapeutics
- Class Antibodies; Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alzheimer's disease
Most Recent Events
- 07 Feb 2024 Phase-III clinical trials in Alzheimer's disease (SC), prior to February 2024 (Neurimmune pipeline, February 2024)
- 07 Feb 2024 Neurimmune Therapeutics terminates phase III/IV ENVISION trial for Alzheimer's disease in Australia, Belgium, Brazil, Canada, Finland, France, Germany, Italy, Japan, South Korea, Mexico, Poland, Portugal, Spain, Sweden, United Kingdom, United States due to sponsor's decision which was not related to safety (NCT05310071)
- 31 Jan 2024 Neurimmune Therapeutics terminates collaboration and license agreement with Biogen for Aducanumab for worldwide